Japan/Korea Joint Phase II Study of Nimotuzumab plus Irinotecan in Patients with Advanced or Recurrent Gastric Cancer

Trial Profile

Japan/Korea Joint Phase II Study of Nimotuzumab plus Irinotecan in Patients with Advanced or Recurrent Gastric Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Nimotuzumab (Primary) ; Irinotecan
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Europe
  • Most Recent Events

    • 19 Jun 2015 Status changed from active, no longer recruiting to completed.
    • 22 Jan 2011 Preliminary results presented at the 2011 Gastrointestinal Cancers Symposium.
    • 20 Jan 2011 Results were presented at the ASCO Gastrointestinal Cancer Symposium on January 20, according to a YM BioSciences media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top